We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thai Cancer Anemia Survey in Chulalongkorn Hospital

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01018043
First Posted: November 23, 2009
Last Update Posted: May 23, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Janssen-Cilag Ltd.,Thailand
  Purpose
The purpose of this study is to create a large Thailand database documenting the severity of anemia and its management in the cancer population.

Condition Intervention Phase
Anemia Cancer Other: Adult Cancer Patients Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Thai Cancer Anemia Survey in Chulalongkorn Hospital

Resource links provided by NLM:


Further study details as provided by Janssen-Cilag Ltd.,Thailand:

Primary Outcome Measures:
  • Number of patients that have anemia during cancer therapy [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Characteristic of each patients example treatment duration,type and chemotherapy using, grade of anemia [ Time Frame: 6 months ]

Enrollment: 264
Study Start Date: April 2006
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
001
Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
Other: Adult Cancer Patients
Tracking anemia management in Adult Cancer Patients

Detailed Description:
Thai Cancer Anemia Study (TCAS) is a prospective survey that will track anemia management in an adult cancer population. This survey is not intended to interfere with standard medical practices for handling anemia. Information on laboratory values including target and achieved hemoglobin (Hb) levels during chemotherapy cycles, use of blood transfusions, iron supplementation, and epoetin will be collected in addition to information on cancer status and treatment. Data on the level that triggers clinicians to decide on the need for anemia therapy will also be collected. Each patient included in the survey will be followed for six months. Observational Study - No investigational drug administered
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Anemic patients with cancer receiving chemotherapy
Criteria

Inclusion Criteria:

  • Patients with cancer

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01018043


Locations
Thailand
Bangkok, Thailand
Sponsors and Collaborators
Janssen-Cilag Ltd.,Thailand
Investigators
Study Director: Janssen-Cilag Ltd Clinical Trial Janssen-Cilag Ltd.
  More Information

Responsible Party: Janssen-Cilag Ltd.,Thailand
ClinicalTrials.gov Identifier: NCT01018043     History of Changes
Other Study ID Numbers: CR011731
TCAS-CU-ONCO-2006
First Submitted: November 19, 2009
First Posted: November 23, 2009
Last Update Posted: May 23, 2014
Last Verified: May 2014

Keywords provided by Janssen-Cilag Ltd.,Thailand:
Cancer Anemia Survey
Chulalongkorn hospital

Additional relevant MeSH terms:
Anemia
Hematologic Diseases